10-Q: Arrowhead Pharmaceuticals Reports Q1 2025 Results, Highlights Sarepta Collaboration and Regulatory Progress

Arrowhead Pharmaceuticals' Q1 2025 results reveal increased R&D spending, a major collaboration with Sarepta, and progress on regulatory submissions.

Summary

• Arrowhead Pharmaceuticals reported a net loss of $173.1 million for the quarter ended December 31, 2024, compared to a net loss of $132.9 million for the same period in 2023.
• The increased loss is primarily attributed to higher research and development expenses as the company's pipeline expands.
• Revenue for the quarter was $2.5 million, down from $3.6 million in the prior year.
• Key developments include the submission of a New Drug Application (NDA) to the FDA for plozasiran, which was accepted for filing with a PDUFA date of November 18, 2025.
• Arrowhead entered into a global collaboration agreement with Sarepta Therapeutics, receiving a $325 million equity investment on February 7, 2025, and expecting a $500 million upfront payment in the second quarter of fiscal 2025.
• GSK dosed the fifth patient in a Phase 2 trial, triggering a $2.5 million milestone payment to Arrowhead, which was paid in the second quarter of fiscal 2025.
• The company's cash, cash equivalents, and restricted cash totaled $53.9 million, with $499.0 million in available-for-sale securities as of December 31, 2024.
• Arrowhead expects its current resources to fund operations for at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is experiencing increased losses, it has secured a significant collaboration with Sarepta and is making progress on regulatory submissions. The company also expects to have sufficient liquidity to fund operations for at least the next twelve months.

Positives

• FDA accepted the NDA for plozasiran.
• The Sarepta collaboration provides significant funding and potential future milestone payments up to $10 billion.
• ARO-CFB study shows promising results with significant protein reduction and pathway inhibition.
• ARO-ALK7 is progressing towards clinical trials as a potential obesity treatment.

Negatives

• Net loss increased to $173.1 million, driven by higher R&D expenses.
• Revenue decreased to $2.5 million from $3.6 million in the same quarter of the previous year.
• Cash and investments decreased by $128.0 million during the quarter.

Risks

• Continued significant investment is required for research and development activities.
• The company is subject to risks associated with clinical trials and regulatory approvals.
• The company is subject to inflationary pressure on goods and services and the labor market.

Future Outlook

The company expects to have sufficient liquidity to fund operations for at least the next twelve months.

Industry Context

The announcement reflects the ongoing trend of pharmaceutical companies focusing on RNAi therapeutics and strategic collaborations to advance drug development pipelines.

Comparison to Industry Standards

• Arrowhead's collaboration with Sarepta is similar to other partnerships in the biotech industry, such as the collaboration between Alnylam Pharmaceuticals and Sanofi Genzyme.
• The milestone payments in the Sarepta agreement are comparable to other deals in the rare disease space.
• The company's cash position is in line with other biotech companies at a similar stage of development.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline development and partnerships.
• Employees: Continued employment and potential for growth within the company.
• Patients: Potential for new treatments for intractable diseases.

Next Steps

• Continue to develop and advance its pipeline and partnered candidates.
• Advance plozasiran through the regulatory approval process.
• Continue enrollment of certain cohorts of a Phase 1/2 study.

Key Dates